Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

.com.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

     
'"/>




Page: 1 2 3 4 5 

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Nov. 1, 2010 LitePoint Corporation, the leader in ... Health Alliance, along with other technology leaders. ... of personal healthcare and to establish a system of ... for all people. "Wireless will be ...
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
Cached Medicine Technology:LitePoint Joins Continua Health Alliance 2China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Dwell ... VP, Brandon Huff as Executive Vice President of Digital ... business units, which represented a large portion of Yahoo's ... growth as Dwell develops a fully-integrated commerce unit to ... of experience monetizing digital content for leading firms in ...
(Date:5/24/2013)... News) -- Low-income, minority parents have more realistic ... more open to vaccinating their daughters against the ... study contends. Conversely, white, middle-class parents are ... daughters, according to researchers from the Boston University ... get an HPV-related cancer each year, many of ...
(Date:5/24/2013)... 2013 The Dictation Source recently added ... clients. As a result of its National marketing efforts, ... 20 states around the nation. , Since 1991, The ... to the healthcare industry . Dictation Source is owned ... years of clinical work experience to provide the solutions ...
(Date:5/24/2013)... 24 (HealthDay News) -- About one in five parents ... take up smoking, drinking or illicit drug use, a ... say experts at the Substance Abuse and Mental Health ... are actually one of the most influential forces helping ... "Surveys of teens repeatedly show that parents can ...
Breaking Medicine News(10 mins):Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2
... Myeloma ( www.ManagingMyeloma.com ), an accredited ... for fellows in oncology to win a scholarship to ... Meeting in New Orleans, Louisiana. The scholarship includes registration ... for meals. , During the conference, the ...
... ... designed to inform our users that the life saving medications they or their loved ... ... -- Recently, WarrantyElephant met with the founder of AllergySense.com, Rhonda Lewis, a WarrantyElephant user, ...
... ... knee amputee, and world record holder in over 10 events in running and triathlon set ... Spirit of the Prairie 100 mile Trail Run in Cassoday, Kansas, Ms. Palmerio-Winters not only ... and finished in 8th place overall. , , ...
... ZURICH, Switzerland, October 15 ... 17 and 18 October 2009. Medical staff, but,particularly administrators ... exceptional introduction to the latest achievements,in football medicine and ... all levels of play. , ...
... Calif., Oct. 14 Beckman Coulter, Inc. (NYSE: BEC ... Thursday, October 29, 2009, at 5:00 p.m. ET to discuss ... released after the market closes. , (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ... 516-3365 or (706) 679-3246 and asking for the Beckman Coulter ...
... , TACOMA, Wash., Oct. 14 Spectrum Pension Consultants, a ... to announce that the 2009 Spectrum Open raised over $100,000, ... oncology unit at St. Joseph,s Hospital. , "This event was ... a participation and fundraising perspective. It was incredible to watch ...
Cached Medicine News:Health News:Managing Myeloma Website Announces Fellow Scholarship Program to Attend and Report on Annual American Society of Hematology in New Orleans 2Health News:WarrantyElephant Launches "MediElephant" a New Medication Reminder Service Inspired by WarrantyElephant User Rhonda Lewis, Founder of AllergySense 2Health News:First Female Amputee To Run a 100 Mile Trail Run Wins the Race 2Health News:FIFA Medical Conference, 17 and 18 October 2009 in Zurich 2Health News:FIFA Medical Conference, 17 and 18 October 2009 in Zurich 3Health News:4th Annual Spectrum Open: A Big Success 2
Portable shields for your safety and convenience....
Portable shields for your safety and convenience....
... Marshield manufactures standard and custom shields and barriers ... for low level or high level radiation shielding, ... 99.95% pure lead, lead acrylic, lead glass, lead ... materials. We can offer shielding from 1/32" thick ...
Full-Height Radiation Barriers provide full-body shielding and reduce eye strain during extended procedures....
Medicine Products: